Apoptosis, proliferation, and Fas (APO-I, CD95)/Fas ligand expression in medullary carcinoma of the breast

被引:0
|
作者
Yakirevich, E
Maroun, L
Cohen, O
Izhak, OB
Rennert, G
Resnick, MB
机构
[1] Lady Davis Carmel Med Ctr, Dept Pathol, IL-34362 Haifa, Israel
[2] Rambam Med Hosp, Dept Pathol, Haifa, Israel
[3] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[4] Lady Davis Carmel Med Ctr, Dept Surg, IL-34362 Haifa, Israel
[5] Lady Davis Carmel Med Ctr, Dept Community Med & Epidemiol, IL-34362 Haifa, Israel
来源
JOURNAL OF PATHOLOGY | 2000年 / 192卷 / 02期
关键词
breast; medullary carcinoma; apoptosis; TUNEL; proliferation; PCNA; Fas; FasL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Medullary carcinoma (MC) of the breast is a unique subtype of infiltrating ductal carcinoma that is characterized by a prominent lymphoid infiltrate and improved prognosis. Activated granzyme B+/CD8(+) cytotoxic T-lymphocytes (CTLs) infiltrating tumour cell nests constitute a major subset within the lymphoid infiltrate. As CTLs destroy target tumour cells by triggering apoptosis, it mould be of interest to determine whether the apoptotic rate in MC is increased. This study evaluates the extent of apoptosis in relation to Fas (APO-1, CD95)/Fas ligand (FasL) expression in MC. Fourteen cases of typical MC (TMC) and 15 cases of atypical MC (AMC) classified according to the Ridolfi criteria, as well as 19 cases of poorly differentiated infiltrating ductal carcinoma (PDC) were evaluated. The apoptotic index (AI) was assessed by the TUNEL method on paraffin-embedded tissue. Cell proliferation was evaluated immunohistochemically by PCNA staining. The level of Fas/FasL expression was determined semiquantitatively by immunohistochemistry using a four-grade scoring system. The AI was significantly increased in TMC and AMC as opposed to the PDC subgroup (2.2 +/- 0.8, 2.1 +/- 0.8, and 1.3 +/- 0.6, respectively; p < 0.05). A significant proportion (31.8 +/- 7.9% in TMC and 25.8 +/- 9.7% in AMC) of the apoptotic tumour cells within tumour nests mere in close contact with CD3(+) lymphocytes. Increased apoptosis was not accompanied by increased proliferation of tumour cells. The extent of Fas expression did not differ between the three subgroups. FasL was expressed both by tumour infiltrating lymphocytes in MC and by tumour epithelium in all three subgroups. The observation that the majority of MCs express Fas and are infiltrated by lymphocytes expressing FasL suggests that increased apoptosis in MC is mediated by Fas/FasL. However, our observation that the majority of MCs also express Fast and the fact that tumours co-expressing Fas and FasL did not show increased apoptosis suggest that there may be additional cytotoxic pathways that lead to tumour apoptosis in MC. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:166 / 173
页数:8
相关论文
共 50 条
  • [1] Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction
    Debatin, KM
    Beltinger, C
    Bohler, T
    Fellenberg, J
    Friesen, C
    Fulda, S
    Herr, I
    Los, M
    Scheuerpflug, C
    Sieverts, H
    Stahnke, K
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) : 405 - 410
  • [2] Fas/CD95/Apo-I activates the acidic sphingomyelinase via Caspases
    Brigit Brenner
    Klaus Ferlinz
    Heike Grassmé
    Michael Weller
    Ursula Koppenhoefer
    Johannes Dichgans
    Konrad Sandhoff
    Florian Lang
    Erich Gulbins
    Cell Death & Differentiation, 1998, 5 : 29 - 37
  • [3] Fas/CD95/Apo-I activates the acidic sphingomyelinase via caspases
    Brenner, B
    Ferlinz, K
    Grassmé, H
    Weller, M
    Koppenhoefer, U
    Dichgans, J
    Sandhoff, K
    Lang, F
    Gulbins, E
    CELL DEATH AND DIFFERENTIATION, 1998, 5 (01): : 29 - 37
  • [4] Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack
    O'Connell, J
    Bennett, MW
    O'Sullivan, GC
    Collins, JK
    Shanahan, F
    DISEASES OF THE ESOPHAGUS, 1999, 12 (02): : 83 - 89
  • [5] Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma
    Gross, N
    Balmas, K
    Brognara, CB
    Tschopp, J
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (01): : 111 - 114
  • [6] Somatic mutations in the death domain of the Fas (Apo-I/CD95) gene in gastric cancer
    Park, WS
    Oh, RR
    Kim, YS
    Park, JY
    Lee, SH
    Shin, MS
    Kim, SY
    Kim, PJ
    Lee, HK
    Yoo, NJ
    Lee, JY
    JOURNAL OF PATHOLOGY, 2001, 193 (02): : 162 - 168
  • [7] Characterization of Fas (Apo-1, CD95)-Fas ligand interaction
    Schneider, P
    Bodmer, JL
    Holler, N
    Mattmann, C
    Scuderi, P
    Terskikh, A
    Peitsch, MC
    Tschopp, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (30) : 18827 - 18833
  • [8] Programmed cell death: the influence of CD40, CD95 (Fas or Apo-I) and their ligands
    Laytragoon-Lewin, N
    MEDICAL ONCOLOGY, 1998, 15 (01) : 15 - 19
  • [9] Programmed cell death: the influence of CD40, CD95 (Fas or Apo-I) and their ligands
    N Laytragoon-Lewin
    Medical Oncology, 1998, 15 : 15 - 19
  • [10] Fas (CD95/Apo-1)/Fas ligand expression in neonates with pontosubicular neuron necrosis
    Van Landeghem, FKH
    Felderhoff-Mueser, U
    Moysich, A
    Stadelmann, C
    Obladen, M
    Brück, W
    Bührer, C
    PEDIATRIC RESEARCH, 2002, 51 (02) : 129 - 135